This also provides a rationale for a combinatorial therapy of TRAIL with mTOR inhibitors in GBM treatment, such as CCI-779, which is widely used clinically and possesses activity against PTEN-deficient GBM tumors [83]. The gene discussed is MTOR; the disease is glioblastoma.